Published in Breast Cancer Res on October 03, 2016
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
A comparison of background correction methods for two-colour microarrays. Bioinformatics (2007) 8.59
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Molecular signatures database (MSigDB) 3.0. Bioinformatics (2011) 8.08
Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene (2006) 4.85
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res (2007) 3.97
CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet (2004) 3.97
CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol (2008) 3.36
Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol (2003) 3.12
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Expression profiling of epithelial plasticity in tumor progression. Oncogene (2003) 2.67
Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res (2006) 2.36
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol (2006) 2.28
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol (2011) 2.02
Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer (2009) 1.96
Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol (2011) 1.94
Isolation and transcription profiling of purified uncultured human stromal stem cells: alteration of gene expression after in vitro cell culture. Mol Biol Cell (2005) 1.91
Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC Cancer (2011) 1.89
The CHEK2 gene and inherited breast cancer susceptibility. Oncogene (2006) 1.62
CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer (2004) 1.56
Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer (2005) 1.55
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res (2008) 1.53
Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage. EMBO J (2007) 1.52
Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res (2011) 1.45
Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol (2011) 1.39
Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet (2004) 1.39
A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat (2006) 1.34
Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Hum Mutat (2008) 1.30
CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol (2012) 1.29
Key signaling nodes in mammary gland development and cancer: β-catenin. Breast Cancer Res (2010) 1.24
Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet (2005) 1.20
Receptor tyrosine kinases activate canonical WNT/β-catenin signaling via MAP kinase/LRP6 pathway and direct β-catenin phosphorylation. PLoS One (2012) 1.18
Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. Mol Cell (2009) 1.18
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer (2007) 1.09
Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. Breast Cancer Res (2015) 1.08
Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res (2010) 1.07
The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology (2014) 1.01
Variants on the promoter region of PTEN affect breast cancer progression and patient survival. Breast Cancer Res (2011) 1.00
Fibroblast growth factor receptor signaling is essential for normal mammary gland development and stem cell function. Stem Cells (2013) 0.97
Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes. Breast Cancer Res Treat (2011) 0.96
Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications. Breast Cancer Res (2011) 0.95
Response to DNA damage of CHEK2 missense mutations in familial breast cancer. Hum Mol Genet (2012) 0.94
Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist (2015) 0.90
Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. Breast Cancer Res Treat (2011) 0.90
Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? Ecancermedicalscience (2013) 0.86
Pathology of breast cancer in women with constitutional CHEK2 mutations. Breast Cancer Res Treat (2005) 0.86
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer (2014) 0.85
Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS (1997) 0.85
Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer. Am J Surg Pathol (2015) 0.83
Survival from breast cancer in patients with CHEK2 mutations. Breast Cancer Res Treat (2014) 0.82
Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet (2014) 5.78
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet (2015) 3.02
POT1 loss-of-function variants predispose to familial melanoma. Nat Genet (2014) 2.40
Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature (2014) 1.88
The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLoS Genet (2015) 1.87
Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet (2015) 1.47
Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nat Genet (2017) 1.44
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA (2017) 1.43
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA (2015) 1.26
Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. EBioMedicine (2015) 1.24
Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat Genet (2015) 1.23
Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2014) 1.22
Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat Genet (2015) 1.05
Automated measurement of volumetric mammographic density: a tool for widespread breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev (2014) 1.01
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. J Natl Cancer Inst (2022) 0.97
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet (2016) 0.95
Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet (2014) 0.95
Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget (2016) 0.93
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. Cancer Res (2015) 0.92
Reproducibility of telomere length assessment: Authors' Response to Damjan Krstajic and Ljubomir Buturovic. Int J Epidemiol (2015) 0.92
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet (2016) 0.92
BRCA2 hypomorphic missense variants confer moderate risks of breast cancer. Cancer Res (2017) 0.91